title: Health economic considerations in the management of type 2 diabetes.
abstract: The number of therapeutic options for people with type 2 diabetes is increasing. Large-scale clinical trials have delineated the health benefits of tight glycemic control with these interventions, including the reduction of long-term diabetes-related complications. These long-term complications compromise quality of life and ultimately account for mortality in most patients with diabetes. Despite the high price tag of managing the long-term complications of hyperglycemia, few economic incentives have been presented for investing in intensive glycemic control. Recent cost-benefit analyses, however, provide insight into the major cost drivers that yield a short-term return on investment for preventive measures. This article highlights cost-effective measures that have been successfully utilized in the managed care setting to simultaneously improve health and economic outcomes of diabetes within the first few years of implementation.
authors.forename: Jon C
authors.initials: JC
authors.lastname: Clouse
authors.forename: Mark
authors.initials: M
authors.lastname: Zitter
authors.forename: Mary E
authors.initials: ME
authors.lastname: Herman
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D002908:Chronic Disease / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control; D019468:Disease Management; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents